Jennifer Brigitte Green, MD, discusses the management of type 2 diabetes for patients not currently controlled on oral antidiabetic medications.
EP. 1: Treatment Approach for Patients With Type 2 Diabetes
Jennifer Brigitte Green, MD, reviews her treatment approach for managing patients with type 2 diabetes and shares insight on how to identify patients that are uncontrolled with oral antidiabetic agents.
EP. 2: Type 2 Diabetes: Considerations for Achieving Targeted Glycemic Control
Dr Jennifer Brigitte Green addresses clinical considerations for patients with type 2 diabetes who are not responding to their oral antidiabetic agents and discusses her strategy for insufficient target glycemic control with insulin regimens.
EP. 3: Clinical Inertia in Treatment of Type 2 Diabetes
Jennifer Brigitte Green, MD, discusses the reasoning behind clinical inertia in treating patients with type 2 diabetes and comments on achieving and maintaining glycemic control over an extended period.
EP. 4: Fixed-Ratio Combinations for Type 2 Diabetes
Dr Jennifer Brigitte Green considers the patient selection for fixed-ratio combinations of basal insulin and GLP-1 receptor agonists among patients with type 2 diabetes and provides insight around Medicare patient access to insulin and injectable medications.
EP. 5: Managing Type 2 Diabetes With Fixed-Ratio Combinations
Rodolfo J. Galindo, MD, provides insight on the benefit of fixed-ratio combinations of basal insulin and GLP1 agonists for the optimal management of type 2 diabetes.
EP. 6: LixiLan-O and DUAL Studies in Type 2 Diabetes
A key opinion leader reviews clinical data for newly approved injectable medications, iGlarLixi and iDegLira, for the management of type 2 diabetes as seen in the LixiLan-O and DUAL studies.
EP. 7: Advantages of Using Fixed-Ratio Combinations in Type 2 Diabetes
Rodolfo J. Galindo, MD, comments on the benefits of fixed-ratio combination therapies for the management of type 2 diabetes compared with premixed insulin.
EP. 8: AMCP Nexus 2021 Updates on iGlarLixi in Type 2 Diabetes
An expert in endocrinology reviews updates from the AMCP Nexus 2021 conference on treatment persistence and adherence with iGlarLixi versus free-dose combinations of basal insulin and GLP-1 receptor agonists, and shares insight on future directions for disease management.
2 Commerce Drive Cranbury, NJ 08512